Incidence rates of tuberculosis in chronic hepatitis C infected patients with or without interferon based therapy: A population-based cohort study in Taiwan

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Lin, Shang Yi ^a,b   Chen, Tun Chieh ^a   Lu, Po Liang ^a,b,c   Lin, Chun Yu ^a,b   Lin, Wei Ru ^a   Yang, Yi Hsin ^a,d   Chen, Yen Hsu ^a,b,c  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL CHIAO TUNG UNIVERSITY   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Hepatitis C virus; Interferon; Tuberculosis

Indexed keywords

ALPHA INTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; AGED; ALCOHOL LIVER CIRRHOSIS; AMBULATORY CARE; ARTICLE; ASCITES; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DATA BASE; DISEASE SEVERITY; ESOPHAGUS VARICES; FEMALE; HEPATIC ENCEPHALOPATHY; HEPATITIS C; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NATIONAL HEALTH INSURANCE; NONALCOHOLIC FATTY LIVER; POPULATION RESEARCH; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TAIWAN; TUBERCULOSIS; YOUNG ADULT; CASE CONTROL STUDY; COINFECTION; FACTUAL DATABASE; HEPATITIS C, CHRONIC;

ADULT; AGED; ANTIVIRAL AGENTS; CASE-CONTROL STUDIES; COHORT STUDIES; COINFECTION; DATABASES, FACTUAL; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RIBAVIRIN; RISK FACTORS; TAIWAN; TUBERCULOSIS; YOUNG ADULT;

EID: 84924048386     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-014-0705-y     Document Type: Article

References (38)

1. National Institutes of Health: National institutes of health consensus development conference statement: management of hepatitis C: 2002 June 10-12, 2002. Hepatology 2002, 36(5 Suppl 1):3-20.
2. Strader DB, Wright T, Thomas DL, Seeff LB: Diagnosis, management, and treatment of hepatitis C. Hepatology 2004, 39:1147-1171.
3. European Association for the Study of the Liver: EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2011, 55:245-264.
4. Ghany MG, Strader DB, Thomas DL, Seeff LB: Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009, 49:1335-1374.
5. Isaacs A, Lindenmann J: Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 1957, 147:258-267.
6. Gonza'lez-Navajas JM, Lee J, David M, Raz E: Immunomodulatory functions of type I interferons. Nat Rev Immunol 2012, 12:125-135.
7. Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG, Orme IM: Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med 1993, 178:2243-2247.
8. Giacomini E, Remoli ME, Gafa V, Pardini M, Fattorini L, Coccia EM: IFN-beta improves BCG immunogenicity by acting on DC maturation. J Leukoc Biol 2009, 85:462-468.
9. Desvignes L, Wolf AJ, Ernst JD: Dynamic roles of type I and type II IFNs in early infection with Mycobacterium tuberculosis. J Immunol 2012, 188:6205-6215.
10. Giosue S, Casarini M, Alemanno L, Galluccio G, Mattia P, Pedicelli G, Rebek L, Bisetti A, Ameglio F: Effects of aerosolized interferon-alpha in patients with pulmonary tuberculosis. Am J Respir Crit Care Med 1998, 158:1156-1162.
11. Giosue S, Casarini M, Ameglio F, Zangrilli P, Palla M, Altieri AM, Bisetti A: Aerosolized interferon-alpha treatment in patients with multi-drug-resistant pulmonary tuberculosis. Eur Cytokine Netw 2000, 11:99-104.
12. Bouchonnet F, Boechat N, Bonay M, Hance AJ: Alpha/beta interferon impairs the ability of human macrophages to control growth of Mycobacterium bovis BCG. Infect Immun 2002, 70:3020-3025.
13. Blanchard DK, Michelini-Norris MB, Djeu JY: Interferon decreases the growth inhibition of Mycobacterium avium-intracellulare complex by fresh human monocytes but not by culture-derived macrophages. J Infect Dis 1991, 164:152-157.
14. Manca C, Tsenova L, Bergtold A, Freeman S, Tovey M, Musser JM, Barry CE 3rd, Freedman VH, Kaplan G: Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-alpha /beta. Proc Natl Acad Sci U S A 2001, 98:5752-5757.
15. Fried MW: Side effects of therapy of hepatitis C and their management. Hepatology 2002, 36:S237-S244.
16. Kumar KS, Russo MW, Borczuk AC, Brown M, Esposito SP, Lobritto SJ, Jacobson IM, Brown RS Jr: Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C. Am J Gastroenterol 2002, 97:2432-2440.
17. Ramos-Casals M, Mañá J, Nardi N, Brito-Zerón P, Xaubet A, Sánchez-Tapias JM, Cervera R, Font J, HISPAMEC Study Group: Sarcoidosis in patients with chronic hepatitis C virus infection: analysis of 68 cases. Medicine (Baltimore) 2005, 84:69-80.
18. Farah R, Awad J: The association of interferon with the development of pulmonary tuberculosis. Int J Clin Pharmacol Ther 2007, 45:598-600.
19. Rodríguez-Medina B, Blanes M, Vinaixa C, Aguilera V, Rubín A, Prieto M, Berenguer M: Haemophagocytic syndrome in a liver transplant patient during treatment with Telaprevir. Ann Hepatol 2013, 12:974-978.
20. Telesca C, Angelico M, Piccolo P, Nosotti L, Morrone A, Longhi C, Carbone M, Baiocchi L: Interferon-alpha treatment of hepatitis D induces tuberculosis exacerbation in an immigrant. J Infect 2007, 54:e223-e226.
21. Sabbatani S, Manfredi R, Marinacci G, Pavoni M, Cristoni L, Chiodo F: Reactivation of severe, acute pulmonary tuberculosis during treatment with pegylated interferon-alpha and ribavirin for chronic HCV hepatitis. Scand J Infect Dis 2006, 38:205-208.
22. Babudieri S, Soddu A, Murino M, Molicotti P, Muredda AA, Madeddu G, Fois AG, Zanetti S, Pirina P, Mura MS: Tuberculosis screening before anti-hepatitis C virus therapy in prisons. Emerg Infect Dis 2012, 18:689-691.
23. Chen CH, Yang PM, Huang GT, Lee HS, Sung JL, Sheu JC: Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants. J Formos Med Assoc 2007, 106:148-155.
24. Centers for Disease Control, Taiwan: Statistics of communicable diseases and surveillance report, Republic of China [accessed 15.06.13], http://www.cdc.gov.tw/uploads/files/201301/472cb943-8774-4015-bcd6-ca27e85524e0.pdf ; 2011.
25. Cheng SH, Chen CC, Chang WL: Hospital response to a global budget program under universal health insurance in Taiwan. Health Policy 2009, 92:158-164.
26. Hsu CS, Kao JH, Chao YC, Lin HH, Fan YC, Huang CJ, Tsai PS: Interferon-based therapy reduces risk of stroke in chronic hepatitis C patients: a population-based cohort study in Taiwan. Aliment Pharmacol Ther 2013, 38:415-423.
27. Asian Pacific Association for the Study of the Liver (APASL) Hepatitis C Working Party, McCaughan GW, Omata M, Amarapurkar D, Bowden S, Chow WC, Chutaputti A, Dore G, Gane E, Guan R, Hamid SS, Hardikar W, Hui CK, Jafri W, Jia JD, Lai MY, Wei L, Leung N, Piratvisuth T, Sarin S, Sollano J, Tateishi R: Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol 2007, 22:615-633.
28. Li SY, Chen TJ, Chung KW, Tsai LW, Yang WC, Chen JY, Chen TW: Mycobacterium tuberculosis infection of end-stage renal disease patients in Taiwan: a nationwide longitudinal study. Clin Microbiol Infect 2011, 17:1646-1652.
29. Lin HH, Ezzati M, Chang HY, Murray M: Association between tobacco smoking and active tuberculosis in Taiwan: prospective cohort study. Am J Respir Crit Care Med 2009, 180:475-480.
30. Lobue P, Menzies D: Treatment of latent tuberculosis infection: an update. Respirology 2010, 15:603-622.
31. Davis RM, Novotny TE: The epidemiology of cigarette smoking and its impact on chronic obstructive pulmonary disease. Am Rev Respir Dis 1989, 140:S82-S84.
32. Pérez-Elías MJ, García-San Miguel L, González García J, Montes Ramírez ML, Muriel A, Machín-Lázaro JM, Martínez-Baltanás A, Zamora F, Moreno A, Martín-Dávila P, Quereda C, Gómez-Mampaso E, Moreno S: Tuberculosis complicating hepatitis C treatment in HIV-infected patients. Clin Infect Dis 2009, 48:e82-e85.
33. Hayat AS, Shaikh N, Masood N: Study for frequency and aetiology of lymphadenopathy during combination therapy for chronic hepatitis C (pegylated interferon alpha plus ribavirin) at a tertiary care hospital in Hyderabad. J Pak Med Assoc 2011, 61:986-989.
34. Liu CH, Liu CJ, Lin CL, Liang CC, Hsu SJ, Yang SS, Hsu CS, Tseng TC, Wang CC, Lai MY, Chen JH, Chen PJ, Chen DS, Kao JH: Pegylated interferon-a-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis 2008, 47:1260-1269.
35. Christou L, Pappas G, Falagas ME: Bacterial infection-related morbidity and mortality in cirrhosis. Am J Gastroenterol 2007, 102:1510-1517.
36. Lo HY, Suo J, Chang HJ, Yang SL, Chou P: Risk Factors associated with death in a 12-month cohort analysis of tuberculosis patients: 12-month follow-up after registration. Asia Pac J Public Health 2011 Dec 23. [Epub ahead of print]
37. El-Serag HB, Anand B, Richardson P, Rabeneck L: Association between hepatitis C infection and other infectious diseases: a case for targeted screening? Am J Gastroenterol 2003, 98:167-174.
38. Jick SS, Lieberman ES, Rahman MU, Choi HK: Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum 2006, 55:19-26.